Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 548

1.

Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry.

Beltran L, Ahmad AS, Sandu H, Kudahetti S, Soosay G, Møller H, Cuzick J, Berney DM; Transatlantic Prostate Group.

Am J Surg Pathol. 2018 Dec 7. doi: 10.1097/PAS.0000000000001202. [Epub ahead of print]

PMID:
30531531
2.

Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply.

Brentnall AR, Buist DSM, Cuzick J.

JAMA Oncol. 2018 Nov 15. doi: 10.1001/jamaoncol.2018.5102. [Epub ahead of print] No abstract available.

PMID:
30452738
3.

Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention.

Pegington M, Evans DG, Howell A, Donnelly LS, Wiseman J, Cuzick JM, Harvie MN.

Eur J Cancer Prev. 2018 Nov 15. doi: 10.1097/CEJ.0000000000000493. [Epub ahead of print]

PMID:
30444752
4.

Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976. [Epub ahead of print]

PMID:
30412281
5.

Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Brenner A, Arribas M, Cuzick J, Jairath V, Stanworth S, Ker K, Shakur-Still H, Roberts I.

Trials. 2018 Oct 1;19(1):533. doi: 10.1186/s13063-018-2900-4.

6.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.

7.

Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.

Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL.

Elife. 2018 Sep 4;7. pii: e37294. doi: 10.7554/eLife.37294.

8.

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.

Lo LL, Milne RL, Liao Y, Cuzick J, Terry MB, Phillips KA.

Br J Cancer. 2018 Jul;119(1):36-39. doi: 10.1038/s41416-018-0120-z. Epub 2018 Jun 21.

PMID:
29925933
9.

Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2018 Jun 8;20(1):49. doi: 10.1186/s13058-018-0979-x.

10.

Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively.

Ahmad AS, Parameshwaran V, Beltran L, Fisher G, North BV, Greenberg D, Soosay G, Møller H, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group.

Oncotarget. 2018 Apr 17;9(29):20555-20562. doi: 10.18632/oncotarget.24994. eCollection 2018 Apr 17.

11.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. No abstract available.

PMID:
29733336
12.

Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.

Hackett J, Thorneloe R, Side L, Wolf M, Horne R, Cuzick J, Smith SG.

Breast Cancer Res Treat. 2018 Aug;170(3):633-640. doi: 10.1007/s10549-018-4775-1. Epub 2018 Apr 24.

13.

Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.

Cuzick J.

Br J Cancer. 2018 May;118(9):1155-1161. doi: 10.1038/s41416-018-0039-4. Epub 2018 Apr 23. Review.

PMID:
29681616
14.

Molecular progression to cervical precancer, epigenetic switch or sequential model?

Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J, Lorincz AT.

Int J Cancer. 2018 Apr 21. doi: 10.1002/ijc.31549. [Epub ahead of print]

15.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

16.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J.

Urol Oncol. 2018 Jun;36(6):310.e7-310.e13. doi: 10.1016/j.urolonc.2018.03.011. Epub 2018 Apr 11.

PMID:
29655620
17.

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density.

Brentnall AR, Cuzick J, Buist DSM, Bowles EJA.

JAMA Oncol. 2018 Sep 1;4(9):e180174. doi: 10.1001/jamaoncol.2018.0174. Epub 2018 Sep 13.

18.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Jul 15;143(2):333-342. doi: 10.1002/ijc.31326. Epub 2018 Mar 9.

19.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.

JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524.

20.

A comparison of five methods of measuring mammographic density: a case-control study.

Astley SM, Harkness EF, Sergeant JC, Warwick J, Stavrinos P, Warren R, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Brentnall AR, Cuzick J, Howell T, Evans DG.

Breast Cancer Res. 2018 Feb 5;20(1):10. doi: 10.1186/s13058-018-0932-z.

21.

Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK.

Evans DG, Brentnall AR, Harvie M, Astley S, Harkness EF, Stavrinos P, Donnelly LS, Sampson S, Idries F, Watterson D, Cuzick J, Wilson M, Jain A, Harrison F, Maxwell AJ, Howell A.

BMC Public Health. 2018 Jan 25;18(1):178. doi: 10.1186/s12889-018-5090-9.

22.

The Value of Helicobacter Eradication in Long-term Aspirin Users.

Cuzick J.

J Natl Cancer Inst. 2018 Jul 1;110(7):690-691. doi: 10.1093/jnci/djx289. No abstract available.

23.

Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction.

van Veen EM, Brentnall AR, Byers H, Harkness EF, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J, Evans DGR.

JAMA Oncol. 2018 Apr 1;4(4):476-482. doi: 10.1001/jamaoncol.2017.4881.

24.

SNPs for breast cancer risk assessment.

Cuzick J, Brentnall A, Dowsett M.

Oncotarget. 2017 Nov 3;8(59):99211-99212. doi: 10.18632/oncotarget.22278. eCollection 2017 Nov 21. No abstract available.

25.

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.

Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J.

Ann Oncol. 2018 Feb 1;29(2):504-509. doi: 10.1093/annonc/mdx713.

26.

RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.

Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R, Boggis C, Motion J, Sergeant JC, Adams J, Evans DG.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):58-66. doi: 10.1158/1055-9965.EPI-17-0158. Epub 2017 Nov 2.

27.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

28.

Need for expanded HPV genotyping for cervical screening.

Cuzick J, Wheeler C.

Papillomavirus Res. 2016 Dec;2:112-115. doi: 10.1016/j.pvr.2016.05.004. Epub 2016 Jun 1.

29.

A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2017 Oct 18;19(1):114. doi: 10.1186/s13058-017-0906-6.

30.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

Dubsky P, Curigliano G, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. No abstract available.

31.

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.

Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5.

PMID:
28886907
32.

Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions.

Lorincz AT, Nathan M, Reuter C, Warman R, Thaha MA, Sheaff M, Vasiljevic N, Ahmad A, Cuzick J, Sasieni P.

Oncotarget. 2017 May 18;8(31):50510-50520. doi: 10.18632/oncotarget.17984. eCollection 2017 Aug 1.

33.

Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx137.

34.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B.

Ann Oncol. 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308.

35.

Preventive therapy for cancer.

Cuzick J.

Lancet Oncol. 2017 Aug;18(8):e472-e482. doi: 10.1016/S1470-2045(17)30536-3. Epub 2017 Jul 26. Review.

PMID:
28759386
36.

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.

Petersen LK, Restrepo J, Moreira ED Jr, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Hyatt D, Maansson R, Moeller E, Qi H, Roberts C, Luxembourg A.

Papillomavirus Res. 2017 Jun;3:105-115. doi: 10.1016/j.pvr.2017.03.002. Epub 2017 Mar 16.

37.

Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.

Stankiewicz E, Mao X, Mangham DC, Xu L, Yeste-Velasco M, Fisher G, North B, Chaplin T, Young B, Wang Y, Kaur Bansal J, Kudahetti S, Spencer L, Foster CS, Møller H, Scardino P, Oliver RT, Shamash J, Cuzick J, Cooper CS, Berney DM, Lu YJ.

Sci Rep. 2017 Jul 11;7(1):5124. doi: 10.1038/s41598-017-05209-z.

38.

Preventing invasive breast cancer using endocrine therapy.

Thorat MA, Cuzick J.

Breast. 2017 Aug;34 Suppl 1:S47-S54. doi: 10.1016/j.breast.2017.06.027. Epub 2017 Jul 8. Review.

39.

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).

Smith SG, Sestak I, Howell A, Forbes J, Cuzick J.

J Clin Oncol. 2017 Aug 10;35(23):2666-2673. doi: 10.1200/JCO.2016.71.7439. Epub 2017 Jun 29.

40.

Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing.

Cuzick J, Myers O, Lee JH, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

JAMA Oncol. 2017 Oct 1;3(10):1327-1334. doi: 10.1001/jamaoncol.2017.1040.

41.

Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia.

Vasiljević N, Carter PD, Reuter C, Warman R, Brentnall AR, Carton JR, Cuzick J, Lorincz AT.

Int J Cancer. 2017 Aug 15;141(4):829-836. doi: 10.1002/ijc.30783. Epub 2017 Jun 1.

42.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).

Eur J Cancer. 2017 Jul;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8.

PMID:
28494403
43.

General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey.

Smith SG, Foy R, McGowan J, Kobayashi LC, Burn J, Brown K, Side L, Cuzick J.

Fam Cancer. 2017 Oct;16(4):509-516. doi: 10.1007/s10689-017-9986-9.

44.

Estimating efficacy in trials with selective crossover.

Brentnall AR, Sasieni P, Cuzick J.

Stat Med. 2017 Jul 10;36(15):2333-2346. doi: 10.1002/sim.7275. Epub 2017 Mar 15.

45.

Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population.

Cuzick J, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, Lyons D, Austin J, Stoler MH, Vibat CRT, Dockter J, Robbins D, Billings PR, Erlander MG.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1053-1059. doi: 10.1158/1055-9965.EPI-16-0960. Epub 2017 Feb 21.

46.

Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes.

Smith SG, Foy R, McGowan JA, Kobayashi LC, DeCensi A, Brown K, Side L, Cuzick J.

Br J Gen Pract. 2017 Jun;67(659):e414-e427. doi: 10.3399/bjgp17X689377. Epub 2017 Feb 13. Erratum in: Br J Gen Pract. 2018 Oct;68(675):468.

47.

Breast-Cancer Tumor Size and Screening Effectiveness.

Brentnall AR, Duffy SW, Cuzick J.

N Engl J Med. 2017 Jan 5;376(1):94. doi: 10.1056/NEJMc1614282. No abstract available.

PMID:
28052231
48.

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.

Cuzick J, Brentnall AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

J Clin Oncol. 2017 Mar;35(7):743-750. doi: 10.1200/JCO.2016.69.8944. Epub 2016 Dec 28.

49.

Assessing opportunities for coordinated R&D in early cancer detection and management in Europe.

Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel AC, Hajdúch M, Hill C, Walker I, van Engeland M, Cuzick J, Meijer G.

Int J Cancer. 2017 Apr 1;140(7):1700-1701. doi: 10.1002/ijc.30564. Epub 2016 Dec 27. No abstract available.

50.

Use of the concordance index for predictors of censored survival data.

Brentnall AR, Cuzick J.

Stat Methods Med Res. 2018 Aug;27(8):2359-2373. doi: 10.1177/0962280216680245. Epub 2016 Dec 29.

Supplemental Content

Loading ...
Support Center